Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface

Current Pharmaceutical Design

Volumn 10, Issue 2, 2004, Pages 183-190

  Trial, J ^a   Rice, L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Anemia; Endothelial cell; Erythropoietin; Inflammation; Macrophage; Neocytolysis; Phagocytosis; Red cell; Renal disease

Indexed keywords

AUTACOID; CD36 ANTIGEN; CELL ADHESION MOLECULE; ERYTHROPOIETIN; GAMMA INTERFERON; GROWTH FACTOR; HEPCIDIN; INTERLEUKIN 4; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLSERINE; RECOMBINANT ERYTHROPOIETIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR;

ALTITUDE; ANEMIA; CELL COMMUNICATION; CELL DESTRUCTION; CELL PROLIFERATION; CELL SECRETION; CELL SUBPOPULATION; CHRONIC DISEASE; COSMONAUT; CYTOLYSIS; DRUG DESIGN; DRUG HALF LIFE; ENDOTHELIUM CELL; ERYTHROCYTE; ERYTHROID CELL; ERYTHROPHAGOCYTOSIS; HUMAN; LIVER DYSFUNCTION; MACROPHAGE; MALARIA; METABOLIC DISORDER; NONHUMAN; PHENOTYPE; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION MOLECULES; ENDOTHELIAL CELLS; ERYTHROCYTES; ERYTHROPOIETIN; HUMANS; MACROPHAGES; SPLEEN;

EID: 0346025496     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453423     Document Type: Review

References (124)

1. Koury MJ, Bondurant MC. Review: The molecular mechanism of erythropoietin action. Eur J Biochem 1992; 210: 649-63.
2. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessiemian N, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-8.
3. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93: 2627-36.
4. Trial J, Rice L, Alfrey CP. Erythropoietin withdrawal alters interactions between young red cells, splenic endothelial cells, and macrophages: An in vitro model of neocytolysis. J Invest Med 2001; 49: 335-45.
5. Bennet GD, Kay MMB. Homeostatic removal of senescent murine erythrocytes by splenic macrophages. Exp Hematol 1981; 9: 297-307.
6. Alfrey CP, Rice L, Udden MM, Driscoll TB. Neocytolysis: Physiological down-regulator of red-cell mass. Lancet 1997; 349: 1389-90.
7. Fischer CL, Johnson PC, Berry CA. Red blood cell mass and plasma volume changes in manned space flight. JAMA 1967; 200: 579-83.
8. Udden MM, Driscoll TB, Pickett MH, Leach-Huntoon CS, Alfrey CP. Decreased production of red blood cells in human subjects exposed to microgravity. J Lab Clin Med 1995; 125: 442-9.
9. Alfrey CP, Udden MM, Huntoon CL, Driscoll TB, Pickett MH. Control of the red cell mass in spaceflight. J Appl Physiol 1996; 81: 98-104.
10. Huff RL, Lawrence JH, Siri WE, Wasserman LR, Hennessey TG. Effects of changes in altitude on hematopoietic activity. Medicine and Science in Sports and Exercise 1951; 30: 197-217.
11. Merino CF. Studies of blood formation and destruction in the polycythemia of high altitude. Blood 1950; 5: 1-31.
12. Rice L, Ruiz W, Driscoll TB, Whitley C, Tapia R, Hachey DL, et al. Neocytolysis on descent from altitude: A newly recognized mechanism for the control of red cell mass. Annals Intern Med 2001; 134: 710-2.
13. Berglund B, Girgegard G, Wide L, Philstedt P. Effects of blood transfusions on some haematological variables in endurance athletes. Med Sci Sports Exerc 1989; 21: 637-42.
14. Rice L, Alfrey CP, Driscoll TB, Whitley CE, Hachey DL, Suki W. Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 1999; 33: 59-62.
15. Bratosin D, Mazurier J, Tissier J-P, Slomianny C, Estaquier J, Russo-Marie F, et al. Molecular mechanisms of erythrophagocytosis. Characterization of the senescent erythrocytes that are phagocytized by macrophages. C R Acad Sci 1997; 320: 811-8.
16. Oka K, Sawamura T, Kikuta K-I, Itokawa S, Kume N, Kita T, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 9535-40.
17. Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, Cerami A. Advanced glycosylation end-products on erythrocyte cell surface induced receptor-mediated phagocytosis by macrophages. J Exp Med 1987; 166: 539-49.
18. Kay MMB. Mechanism of removal of senescent cells by human macrophages in situ. Proc Natl Acad Sci USA 1975; 72: 3521-5.
19. Groom AC, Song SH, Lim P, Campling B. Physical characteristics of red cells collected from the spleen. Can J Physiol Pharmacol 1971; 49: 1092-9.
20. Shattil SJ, Cooper RA. Maturation of macroreticulocyte membranes in vivo. J Lab Clin Med 1972; 79: 215-27.
21. Lux SE, John KM. Isolation and partial characterization of a high molecular weight red cell membrane protein complex normally removed by the spleen. Blood 1977; 50: 625-41.
22. Crosby WH. Splenic remodeling of red cell surfaces. Blood 1977; 50: 643-5.
23. Qiu LB, Dickson H, Hajibagheri N, Crocker PR. Extruded erythroblast nuclei are bound and phagocytosed by a novel macrophage receptor. Blood 1995; 85: 1630-9.
24. Telen MJ. Red blood cell surface adhesion molecules: Their possible roles in normal human physiology and disease. Semin Hematol 2000; 37: 130-42.
25. Alon R, Kassner PD, Carr MW, Finger EB, Hemler ME, Springer TA. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 1995; 128: 1243-53.
26. Asch AS, Barnwell J, Silverstein RL, Nachman RL. Isolation of the thrombospondin membrane receptor. J Clin Invest 1987; 79: 1054-61.
27. Leung LL. Role of thrombospondin in platelet aggregation. J Clin Invest 1984; 74: 1764-72.
28. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 1989; 246.
29. Shamri R, Grabovsky V, Feigelson SW, Dwir O, van Kooyk Y, Alon R. Chemokine stimulation of lymphocyte α4 integrin avidity but not of leukocyte function-associated antigen-1 avidity to endothelial ligands under shear flow requires cholesterol membrane rafts. J Biol Chem 2002; 277: 40027-35.
30. Kannan S. E-NTPase/NTPDase: A potential regulatory role in E-kinase/PKA-mediated CD36 activation. Cell Biology International 2003; 27: 153-63.
31. Oldenborg P-A, Zheleznyak A, Fang Y-F, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science 2000; 288: 2051-4.
32. Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 1997; 386: 181-6.
33. Oshima K, Amin ARMR, Suzuki A, Hamaguchi M, Matsuda S. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett 2002; 519: 1-7.
34. Lyons BL, Lynes MA, Burzenski L, Joliat MJ, Hadjout N, Shultz LD. Mechanisms of anemia in SHP-1 protein phosphatase-deficient "viable motheaten" mice. Exp Hematol 2003; 31: 234-43.
35. Oldenborg P-A, Gresham HD, Chen Y, Izui S, Lindberg FP. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 2002; 99: 3500-4.
36. Oldenborg P-A, Gresham HD, Lindberg FP. CD47-signal regulatory α (SIRPα) regulates Fcγ and complement receptor-mediated phagocytosis. J Exp Med 2001; 193: 855-61.
37. Bayraktar M, Dundar S, Kirazli S, Teletar F. Platelet factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J Int Med Res 1994; 22: 90-4.
38. Raugi GJ, Olerud JE, Gown AM. Thrombospondin in early human wound tissue. J Invest Dermatol 1987; 89: 5514.
39. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. J Clin Invest 2001; 107: 1555-62.
40. Baruch DI, Gormley JA, Ma C, Howard RJ, Pasloske BL. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1996; 93: 3497-502.
41. Yamauchi Y, Kuroki M, Imakiire T, Uno K, Abe H, Beppu R, et al. Opposite effects of thrombospondin-1 via CD36 and CD47 on homotypic aggregation of monocytic cells. Matrix Biology 2002; 21: 441-8.
42. Bailly P, Tontii E, Hermand P, Cartron J-P, Gahmberg CG. The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins. Eur J Immunol 1995; 25: 3316-20.
43. Goel MS, Diamond SL. Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma. Blood 2002; 100: 3797-803.
44. v-family integrins through novel integrin-binding mechanisms. Blood 2001; 98: 458-66.
45. Moodley Y, Rigby P, Bundell C, Bunt S, Hayashi H, Misso N, et al. Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36. Am J Pathol 2003; 162: 771-9.
46. Levine P, Celano MJ. Agglutinating specificity for LW factor in guinea pig and rabbit anti-Rh serumes. Science 1967; 156: 1744-6.
47. Ohi H, Tamano M, Sudo S, Okada N. Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins. Am J Kidney Dis 2003; 41: 179-85.
48. Hebert LA, Birmingham DJ, Dillon JJ, Cosio FG, Shen XP. Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35). J Am Soc Nephrol 1994; 4: 1786-91.
49. Hebert LA, Cosio FG, Birmingham DJ, Mahan JD. Biologic significance of the erythrocyte complement receptor: A primate perquisite. J Lab Clin Med 1991; 118: 301-8.
50. Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 1992; 80: 1940-9.
51. Hebert LA, Birmingham DJ, Shen X-P, Cosio FG. Stimulating erythropoiesis increases complement receptor expression on primate erythrocytes. Clin Immunol Immunopathol 1992; 62: 301-6.
52. Pascual M, Danielsson C, Steiger G, Schifferli JA. Proteolytic cleavage of CR1 on human erythrocytes in vivo: Evidence for enhanced cleavage in AIDS. Eur J Immunol 1994; 24: 702-4.
53. Stock RJ, Cilento EV, Reilly FD, McCuskey RS. A compartmental analysis of the splenic circulation in rat. Am J Physiol 1983; 245: H17-21.
54. Montes RAO, Eckman JR, Hsu LL, Wick TM. Sickle erythrocyte adherence to endothelium at low shear: Role of shear stress in propagation of vaso-occlusion. Am J Hematol 2002; 70: 216-27.
55. de Jong K, Rettig MP, Low PS, Kuypers FA. Protein kinase C activation induces phosphatidylserine exposure on red blood cells. Biochemistry 2002; 41: 12562-7.
56. Jindal HK, Ai ZW, Gascard P, Horton C, Cohen CM. Specific loss of protein kinase activities in senescent erythrocytes. Blood 1996; 88: 1479-87.
57. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β. J Clin Invest 1998; 101: 890-8.
58. Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein CD36: A review of its roles in adherence, signal transduction, and transfusion medicine. Blood 1992; 80: 1105-15.
59. Trezzini C, Jungi TW, Spycher MO, Maly FE, Rao P. Human monocytes CD36 and CD16 are signaling molecules. Evidence from studies using antibody-induced chemiluminescence as a tool to probe signal transduction. Immunology 1990; 71: 29-37.
60. Coccia MA, Cooke K, Stoney G, Pistillo J, Del Castillo J, Duryea D, et al. Novel erythropoiesis stimulating protein (darbepoetin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model. Exp Hematol 2001; 29: 1201-9.
61. Berney T, Shibata T, Merino R, Chicheportiche Y, Kindler V, Vassalli P, et al. Murine autoimmune hemolytic anemia resulting from Fc gamma receptor-mediated erythrophagocytosis: protection by erythropoietin but not by interleukin-3, and aggravation by granulocyte-macrophage colony-stimulating factor. Blood 1992; 79: 2960-4.
62. Hanazono Y, Sasaki K, Nitta H, Yazaki Y, Hirai H. Erythropoietin induces tyrosine phosphorylation of the β chain of the GM-CSF receptor. Biochem Biophys Res Commun 1995; 208: 1060-6.
63. Blake TJ, Jenkins BJ, D'Andrea RJ, Gonda TJ. Functional cross-talk between cytokine receptors revealed by activating mutations in the extracellular domain of the β-subunit of the GM-CSF receptor. J Leukoc Biol 2002; 72: 1246-55.
64. Arcasoy MO, Maun NA, Perez L, Forget BG, Berliner N. Erythropoietin mediates terminal granulocytic differentiation of committed myeloid cells with ectopic erythropoietin receptor expression. Eur J Hematol 2001; 67: 77-87.
65. Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, Begley CG. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood 2000; 96: 1588-90.
66. Anagnostou A, Lee ES, Kesseimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-82.
67. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-9.
68. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-4.
69. Vogel V, Kramer HJ, Backer A, Meyer-Lehnert H, Jelkman W, Fandrey J. Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 1997; 10: 289-96.
70. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64: 326-33.
71. Alvarez Arroyo MV, Castilla MA, Pacheco FRG, Tan DR, Riesco A, Casado S, et al. Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J Am Soc Nephrol 1998; 9: 1998-2004.
72. del Peso G, Selgas R, Bajo MA, Fernandez de Castro M, Aguilera A, Cirugeda A, et al. Serum level of vascular endothelial growth factor is influenced by erythropoietin treatment in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 85-9.
73. Nitta K, Uchida K, Kinmata N, Honda K, Kobayashi H, Kawashima A, et al. Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells. Eur J Pharmacol 1999; 373: 121-4.
74. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood 2003; prepublished online April 17.
75. Chong ZZ, Kang J-Q, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-9.
76. Uddin S, Kottegoda S, Stigger D, Platanias LC, Wickrema A. Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. Biochem Biophys Res Commun 2000; 275: 16-9.
77. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44: 77-87.
78. Ikegaya N, Yamamoto T, Takeshita A, Watanabe T, Yonemura K, Miyaji T, et al. Elevated erythropoietin receptor and transforming growth factor-beta1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol 2000; 11: 928-35.
79. Tsunawaki S, Sporn MB, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature 1988; 334: 260-2.
80. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med 1987; 166: 571-6.
81. Sennikov SV, Krysov SV, Injelevskaya TV, Silkov AN, Kozlov VA. Production of cytokines by immature erythroid cells derived from human embryonic liver. Eur Cytokine Netw 2001; 12: 274-9.
82. Seledtsova GV, Seledtsov VI, Taraban VY, Samarin DM, Kozlov VA. A role for interferon-gamma and transforming growth factor-beta in erythroid cell-mediated regulation of nitric oxide in macrophages. Immunology 1997; 91: 109-13.
83. Tsan MF, Lawrence D, White JE. Erythrocyte insufflation-induced protection against oxygen toxicity: role of cytokines. J Appl Physiol 1991; 71: 1751-7.
84. Tsukamoto H. Iron regulation of hepatic macrophage TNFα expression. Free Radical Biol Med 2002; 32: 309-13.
85. Means RT, Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 1995; 13: 32-7.
86. Bertero MT, Caligaris-Cappio F. Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 1997; 82: 375-81.
87. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8.
88. Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. I Invest Med 1999; 47: 204-11.
89. Means RT, Jr. The anaemia of infection. Baillieres Best Pract Res Clin Haematol 2000; 13: 151-62.
90. Hann IM. The normal blood picture in neonates. In: Hann IM, Gibson BES, Letsky EA, Eds. Fetalland Neonatal Haematology. London, Balliere Tindall. 1991; p. 29-50.
91. Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 1986; 67: 46-9.
92. Khoury H, Grimsley E. Oxygen inhalation in nonhypoxic sickle cell patients during vaso-occlusive crisis. Blood 1995; 86: 3998.
93. Vedovato M, De Paoli Vitali E, Dapporto M, Salvatorelli G. Defective erythropoietin production in the anaemia of malaria. Nephrol Dial Transplant 1999; 14: 1043-4.
94. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17 Suppl. 1: 48-52.
95. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest 2000; 106: 337-8.
96. Nussenblatt V, Mukasa G, Metzger A, Ndeezi G, Garrett E, Semba RD. Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria. Clin Diag Lab Immunol 2001; 8: 1164-70.
97. Martiney JA, Sherry B, Metz CN, Espinoza M, Ferrer AS, Calandra T, et al. Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: Possible role in the pathogenesis of malarial anemia. Infect Immun 2000; 68: 2259-67.
98. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60: 386-92.
99. Suliman HB, Logan-Henfrey L, Majiwa PA, ole-Moiyoi O, Feldman BF. Analysis of erythropoietin and erythropoietin receptor gene expression in cattle during acute infection with Trypanosoma congolense. Exp Hematol 1999; 27: 37-45.
100. Mons B, Collins WE, Skinner JC, Star W, Croon J, Kaay H. Plasmodium vivax: in vitro growth and reinvasion in red blood cells of Aolus nancymai. Exp Parasitol 1988; 66: 83-8.
101. Espinosa AM, Sierra AY, Barrero CA, Cepeda LA, Cantor EM, Lombo TB, et al. Expression, polymorphism analysis, reticulocyte binding and serological reactivity of two Plasmodium vivax MSP-1 protein recombinant fragments. Vaccine 2003; 21: 1033-43.
102. Tian LP, Nelson EA, Senok AC, Yu LM, Oppenheimer SJ, Li K. Red cell age and susceptibility to malaria during pregnancy. Acta Obstet Gynecol Scand 1998; 77: 717-21.
103. Stevenson MM, Tam MF, Wolf SF, Sher A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFNγ and TNFα and occurs via a nitric oxide-dependent mechanism. J Immunol 1995; 155: 2545-56.
104. Artavani-Tsakonas K, Riley EM. Innate immune response to malaria: Rapid induction of IFN-γ from human NK cells by live Plasmodium falciparum-infected erythrocytes. J Immunol 2002; 69: 2956-63.
105. Canbessa M, Fabry ME, Blumenfeld N, Nagel RL. Volume-stimulated, C1(-)-dependent K+ efflux is highly expressed in young human red cells containing normal hemoglobin or HbS. J Membr Biol 1987; 97: 97-105.
106. McGoron AJ, Joiner CH, Palascak MB, Claussen WJ, Franco RS. Dehydration of mature and immature sickle red blood cells during fast oxygenation/deoxygenation cycles: Role of KCl cotransport and extracellular calcium. Blood 2000; 95: 2164-8.
107. Cln in human young red cells: association with actin. Biochem J 1997; 327: 609-16.
108. Joiner CH. Cation transport and volume regulation in sickle red blood cells. Am J Physiol 1993; 264: C251-C70.
109. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-9.
110. Barabino GA, McIntire LV, Eskin SG, Udden MM. Endothelial cell interactions with sickle cell, sickle trait, mechanically injured, and normal erythrocytes under controlled flow, Blood 1987; 70: 152-7.
111. Wick TM, Moake JM, Udden MM, McIntire LV. Unusually large von Willebrand factor multimers preferentially promote young sickle and non-sickle erythrocyte adhesion to endothelial cells. Am J Hematol 1993; 42: 284-92.
112. Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood 1993; 81: 2429-38.
113. Hebbel RP, Mohandas N. Sickle cell adherence. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, Eds. Sickle cell disease: Basic principles and clinical practice. Philadelphia, Lippincot-Raven 1996; 217-30.
114. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003; 228: 1-14.
115. Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Egrie JC, et al. Intravenous versus subcutaneous dosing of epoietin alpha in hemodiallysis patients. Am J Kidney Dis 1995; 26: 331-40.
116. Eschbach JW, Egrie JC, Downing MR, Brown JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-8.
117. Adamson JW, Eschbach JW, Finch C. The kidney and erythropoiesis. Blood 1968; 44: 725-33.
118. Polenakovic M, Sikole A. Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol 1996; 7: 1178-82.
119. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999; 274: 24773-8.
120. Adams JC, Monk R, Taylor AL, Ozbek S, Fascetti N, Baumgartner S, et al. Characterization of Drosophila thrombospondin defines an early origin of pentameric thrombospondins. J Mol Biol 2003; 328: 479-94.
121. Barclay AN, Brown MH, Law SKA, McKnight AJ, Tomlinson MG, van der Merwe PA. The leukocyte antigen FactsBook. second ed. San Diego, Academic Press. 1997.
122. Alvarez D, Wiley RE, Jordana M. Cytokine therapeutics for asthma: an appraisal of current evidence and future prospects. Curr Pharm Design 2001; 7(11): 1059-81.
123. Devine DA, Hancock RE. Cationic peptides: distribution and mechanisms of resistance. Curr Pharm Design 2002; 8(9): 703-14.
124. Schein CH. The shape of the messenger: using protein structure information to design novel cytokine-based therapeutics. Curr Pharm Design 2002; 8(24): 2113-29.